NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Drug Manufacturers - General · USD

Pfizer Inc. (PFE) Stock Analysis

Pfizer Inc. (PFE) is a Drug Manufacturers - General stock listed on NYSE and quoted in US Dollar.

PFE

$28.45

−$0.36 (−1.25%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PFE with… →

PFE Key Statistics

As of Sep 4, 2026
Trading
Open
$28.58
Previous Close
$28.81
Day's Range
28.38–28.69
52-Week Range
23.58–29.21
Volume
23.78M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.30
Valuation
Market Cap
$162.16B
P/E Ratio
37.93
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
9.83
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
2.82
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.55
EPS (ttm)Profit attributable to each share over the last twelve months.
0.75
Financials (FY)
Revenue (FY)
$62.58B−1.65%
Net Income (FY)
$7.77B−3.24%
Profit marginThe share of revenue left as profit after all costs and taxes.
6.80%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
5.70B
1-Year Return
+24.06%
Dividend and dates
Dividend
$1.72+5.97%
Ex-Dividend Date
July 24, 2026
Earnings Date
November 3, 2026
Avg Volume
42.62M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PFE Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+20.15%
2025+0.65%
2024−2.22%
2023−41.26%
2022−10.41%
2021+66.69%
2020+3.07%
2019−6.91%
2018+24.82%
2017+15.90%
2016 (partial year)−6.09%

As of September 4, 2026.

PFE Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$62.58B$7.77B12.4%
2024$63.63B$8.03B12.6%
2023$59.55B$2.12B3.6%
2022$101.18B$31.37B31.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$62.58B$46.51B$17.41B$7.77B12.4%
2024$63.63B$45.78B$14.94B$8.03B12.6%
2023$59.55B$34.60B$4.42B$2.12B3.6%
2022$101.18B$66.83B$38.12B$31.37B31.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PFE Dividend History

$1.72+2.4% vs 2024

Dividends per share, 2025 · 4 payments

YearDividends per sharePaymentsChange
2026*$1.293—
2025$1.724+2.4%
2024$1.684+2.4%
2023$1.644+2.5%
YearDividends per sharePaymentsChange
2026 (partial year)$1.293—
2025$1.724+2.4%
2024$1.684+2.4%
2023$1.644+2.5%
2022$1.604+2.6%
2021$1.564+8.2%
2020$1.444+5.6%
2019$1.374+5.9%
2018$1.294+6.3%
2017$1.214+326.7%
2016$0.281—

Most recent payment: $0.43 per share, ex-dividend July 24, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

PFE Valuation vs Drug Manufacturers - General Median

Median of 21 stocks
MetricPFEDrug Manufacturers - General medianvs median
P/E37.9324.6954% above
P/S ratio2.553.1319% below
Profit margin6.80%8.09%1.3 pts below

Medians across 21 Drug Manufacturers - General stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Pfizer Inc. (PFE) is capitalised at $162.16B on the latest close. It is classified in the Drug Manufacturers - General industry, within the Healthcare sector. Headcount on file is 75,000.

Over the past 52 weeks the price has ranged from $23.58 to $29.21. PFE last closed at $28.45 on September 4, 2026. That is −$0.36 (−1.25%) against the previous close. The latest close sits 20.65% above that 52-week low.

Financial Health

In fiscal 2025, Pfizer Inc. reported revenue of $62.58B. Against the prior fiscal year total of $63.63B, that is a change of −1.65%. The same year closed with net income of $7.77B. That is −3.24% against the prior fiscal year. Profit margin runs at 6.8%. That is 1.3 percentage points below the Drug Manufacturers - General median of 8.09%. Trailing earnings per share are 0.75.

Across the 4 fiscal years on file, revenue moves from $101.18B in 2022 to $62.58B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

PFE trades at a trailing price-to-earnings ratio of 37.93. That is 53.62% above the Drug Manufacturers - General median of 24.69. The forward P/E on file is 9.83. The PEG ratio, which sets the P/E against expected earnings growth, reads 2.82. The price-to-sales ratio is 2.55. On price-to-sales that is 18.71% below the Drug Manufacturers - General median of 3.13. 21 Drug Manufacturers - General companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +24.06%. Across 10 years the annualized return works out at +3.11%. The reported beta is 0.3. Annualized volatility over the trailing 10 years is 24.05%.

Growth & Income

Shareholders receive a dividend, yielding 5.97% on the latest price. That is 3.3 percentage points above the Drug Manufacturers - General median yield of 2.7%. At the indicated rate that is $1.72 a share a year. The ex-dividend date on file is July 24, 2026. Dividends are recorded for 11 calendar years; 2026 shows 3 payments totalling $1.29 a share. The year before, 2025, totalled $1.72 a share.

The strongest complete calendar year on file is 2021 at +66.69%; the weakest is 2023 at −41.26%. Of the 9 complete calendar years on file, 5 finished higher. So far in 2026 the price is +20.15%.

Peer Comparison

Pfizer Inc. (PFE) operates in the Drug Manufacturers - General industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Pfizer Inc. PFE $162.16B 37.9
Eli Lilly and Company LLY $1.02T 38.6
Johnson & Johnson JNJ $663.28B 32.0
AbbVie Inc. ABBV $453.19B 73.5

The Drug Manufacturers - General industry average P/E ratio is 24.7x. Pfizer Inc. trades at a P/E of 37.9.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - General Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 NVS

Novartis AG

$304.10B

 AZN

AstraZeneca PLC

$252.33B
View all Drug Manufacturers - General stocks →

Popular Healthcare Stocks

UNH

UnitedHealth Group Incorporated

$356.47B

 AMGN

Amgen Inc.

$236.38B

 TMO

Thermo Fisher Scientific Inc.

$226.94B

 NVO

Novo Nordisk A/S

$206.02B

 ABT

Abbott Laboratories

$187.45B
View all Healthcare stocks →

About Pfizer Inc.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Visit website →